huahaipharm(SH:600521)2022-10-28 16:00Financial Performance - The company's operating revenue for Q3 2022 was ¥2,014,478,938.61, representing a year-over-year increase of 28.93%[4] - The net profit attributable to shareholders for Q3 2022 was ¥226,521,940.42, a significant increase of 206.26% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2022 was ¥254,881,436.49, reflecting a remarkable increase of 739.18% year-over-year[4] - The basic earnings per share for Q3 2022 was ¥0.16, up 166.67% from the previous year[5] - The diluted earnings per share for Q3 2022 was also ¥0.16, marking a 166.67% increase compared to the same period last year[5] - The net profit attributable to shareholders for the year-to-date period was ¥794,518,892.99, reflecting a year-over-year increase of 34.75%[4] - Net profit for the third quarter of 2022 was ¥804,387,508.78, representing a 35.4% increase compared to ¥594,079,162.20 in Q3 2021[19] - Total profit for Q3 2022 was ¥1,023,613,099.31, compared to ¥769,196,944.53 in Q3 2021, marking a 32.9% increase[18] Cash Flow and Investments - The net cash flow from operating activities for Q3 2022 was ¥108,087,994.93, a decrease of 59.41% year-over-year[4] - Cash flow from operating activities for the first three quarters of 2022 was ¥598,834,358.42, a decrease from ¥680,741,615.29 in the same period of 2021[21] - The net cash flow from investing activities was -$1,613,937,040.10, compared to -$1,511,070,936.81 in the previous year, indicating a decrease in investment cash flow[22] - The company reported a net cash outflow from investing activities of ¥956,918,578.56 in 2022, an improvement from a net outflow of ¥1,496,059,346.10 in 2021[28] Assets and Liabilities - Total assets at the end of Q3 2022 amounted to ¥16,891,397,134.24, an increase of 9.20% from the end of the previous year[5] - As of September 30, 2022, the company's total assets amounted to ¥16,891,397,134.24, an increase from ¥15,468,124,894.16 at the end of 2021, representing a growth of approximately 9.16%[14] - Total liabilities reached ¥9,546,520,932.79, compared to ¥8,691,800,745.73, representing an increase of about 9.84%[15] - Long-term borrowings rose to ¥2,632,241,900.00 from ¥1,827,315,850.00, indicating an increase of approximately 44.00%[15] - The company's equity attributable to shareholders increased to ¥7,102,584,007.77 from ¥6,558,842,119.10, reflecting a growth of about 8.30%[15] - Total liabilities reached $7,800,543,721.18, an increase from $7,168,420,297.17, representing a growth of approximately 8.8%[24] - The company's equity totaled $8,647,069,051.86, up from $7,977,024,920.80, indicating an increase of about 8.4%[25] Inventory and Receivables - The company's current assets totaled ¥7,196,597,436.74, compared to ¥6,812,609,308.04 in the previous year, indicating an increase of about 5.66%[12] - Accounts receivable rose to ¥2,317,403,765.50, up from ¥1,849,743,324.64, marking an increase of around 25.38%[12] - Inventory increased significantly to ¥3,285,899,939.60 from ¥2,738,528,577.05, which is an increase of approximately 20.00%[12] - The company’s inventory increased to $2,496,876,456.64 from $2,143,454,539.76, showing a rise of about 16.5%[23] Research and Development - Research and development expenses for Q3 2022 totaled ¥670,476,442.29, an increase of 17.6% from ¥570,006,180.69 in Q3 2021[18] - Research and development expenses increased to ¥299,112,514.85 in 2022, up 33.2% from ¥224,497,625.67 in 2021[26] Tax and Financial Expenses - The company reported a tax expense of ¥219,225,590.53 for Q3 2022, up from ¥175,117,782.33 in Q3 2021[18] - The company’s tax expenses increased to ¥95,069,094.01 in 2022 from ¥75,657,891.09 in 2021, reflecting a rise of 25.7%[27] - The company’s financial expenses showed a significant reduction, with a net financial expense of -¥158,826,268.73 in 2022 compared to ¥96,869,746.67 in 2021[26]